Biotia

For the last fifty years, the way we identify infectious disease has rested on two technologies. Culture grows the pathogen in a petri dish and waits for something to appear. PCR amplifies a specific DNA target the lab decided in advance to look for. Together, they've been the workhorses of modern clinical microbiology, and they've done extraordinary work.

But both have hard ceilings, and we've hit them.

Culture takes 24 to 72 hours, often longer, and misses any organism that won't grow in standard conditions. PCR is faster and more sensitive, but only tells you whether the specific pathogens on the panel are present — it can't see anything you didn't already think to test for. Roughly half of urinary tract infections come back "no growth" from a standard culture. Many serious joint infections, post-surgical infections, and infections in immunocompromised patients go undiagnosed for days while a clinician guesses at empiric antibiotics. Surveillance for emerging threats — H5N1, mpox, the next COVID — depends on someone, somewhere, having both the foresight to design a test and the infrastructure to run it. Most of the world has neither.

You can't fight what you can't see.

The Opportunity: Sequence Everything, Identify Anything

Next-generation sequencing changes the question. Instead of asking "is this specific organism present?" a metagenomic NGS test reads every fragment of DNA and RNA in the sample, then matches the fragments against a reference library that covers thousands of pathogens at once. Done well, it's more sensitive than culture, more comprehensive than PCR, and can profile antimicrobial resistance from the same run. The technology that made this affordable — sequencing costs have fallen by more than two orders of magnitude in fifteen years — has finally crossed the threshold where this can run as a routine clinical test, not just a research project.

The hard parts are the parts that have nothing to do with the sequencer: clinical validation, regulatory approval, the machine-learning models that turn raw read data into a diagnosis, the workflow that gets a sample from a patient or a mosquito trap onto the platform, and the trust that gets a clinician or a public health agency to act on the result.

The next generation of infectious disease care is built on sequencing every sample and letting AI tell us what's in it.

Genomics and AI, From Bedside to Biosphere

Biotia's platform does three critical things, each with a different buyer and a different mission:

1. Replaces culture and PCR for the hardest clinical infections. BIOTIA-DX and BIOTIA-ID are clinically validated metagenomic NGS assays — CLEP-approved in New York State, published in Microbiology Spectrum, and used for immunocompromised patients, complicated UTIs, joint infections, and other cases where culture and PCR aren't enough. The platform now also reports clinical antimicrobial resistance profiles directly from the same sample.
2. Brings advanced UTI care to patients at home. BIOTIA-ID Urine ships a sample collection kit, runs the metagenomic test, and pairs the result with virtual care from clinicians trained specifically on recurrent UTIs — a "test to treat" model that meets patients where they actually are.
3. Builds the global pandemic early warning layer. GeoSeeq is Biotia's surveillance platform. Local labs in diagnostic deserts — currently 12 Watchtower sites globally — sequence pathogens from patients, mosquitoes, and environmental reservoirs. The data flows into a shared global stream, layered with climate and health data, that lets governments, NGOs, and global health bodies detect outbreaks before they become pandemics.

The same underlying capability — affordable sequence-based pathogen detection plus the AI to interpret it — serves both an individual patient with a stubborn UTI and the World Health Organization tracking a potential spillover event. The clinical business funds the platform. The platform powers the public health mission.

Biotia's work has earned partnerships and recognition from across the infectious-disease ecosystem: The Rockefeller Foundation, Mayo Clinic Platform, Weill Cornell Medicine, Cornell Tech, SUNY Downstate, MetaSUB, and Fiocruz in Brazil. The company was invited to present its pandemic early-warning vision to the UN General Assembly alongside WHO, the Pasteur Institute, and Fiocruz, and has won the CAMDA challenge (the leading benchmark in microbial AI) two years running. Coverage in Wired, TedMed, GenomeWeb, and the UN system has tracked the work since the early days.

Why We Invested

Three things had to be true at the same time for sequencing-based infectious disease diagnostics to break into routine clinical and public health use, and they finally are:

• Sequencing economics finally work at the point of care. NGS costs have fallen far enough that a metagenomic test can compete on price with the workups it replaces — and the clinical evidence base is now mature enough that payers and clinicians can act on the results.
• The AI is the hard part, and Biotia is winning on it. Identifying pathogens from messy metagenomic reads, profiling resistance, and distinguishing signal from contamination is exactly the class of problem ML solves better than expert humans. Two consecutive CAMDA wins are evidence the platform's model architecture is at the frontier.
• Clinical and public health markets are converging on one stack. Hospitals diagnosing patients, agencies tracking outbreaks, and global bodies preparing for the next pandemic all need the same underlying capability. Biotia is one of the very few companies building for all of them — and the only one that has translated that into shipped clinical products, real D2C revenue, and an active global surveillance network at the same time.

Biotia's team has spent years doing the unglamorous work of clinical validation, regulatory approval, and partnership-building with the institutions — Mayo, Weill Cornell, the Rockefeller Foundation, Fiocruz — that determine whether a diagnostic ever actually reaches a patient. That work doesn't make headlines. It's also exactly what builds a durable, defensible position in healthcare.

We invest in pathogens at the speed of light. Biotia is helping us catch up.